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Abstract
Investigator initiated randomized clinical trials (IITs) are the backbone of academic clinical 
research. IITs complement the large clinical studies sponsored by industry and address questions, 
which are usually not the main focus of a commercially directed research but have the purpose to 
confirm, improve or refute clinically important questions with regard to diagnostic and therapeutic 
approaches in patient care. The aim of this review is to illustrate the necessary steps to start and 
complete an IIT in the field of inflammatory bowel diseases (IBD) in the US. The initial 
milestones for an investigator include structuring a protocol, planning and building of the trial 
infrastructure, accurately estimating the costs of the trial and gauging the time span for 
recruitment. Once the trial has begun it is important to keep patient recruitment on target, monitor 
of the data quality, and document treatment emergent adverse events. This article provides a 
framework for the different phases of an IIT and outlines potential hurdles, which could hinder a 
successful execution.
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Clinical trials conducted by pharmaceutical companies are designed to improve or expand 
available medical treatments and are aligned with the sponsor’s commercial interest. 
“Investigator initiated trials” (IITs) typically have the same objectives while being 
independent of commercial interests. In the context of IITs, the Food and Drug 
Administration (FDA) uses a specific nomenclature and distinguishes between an 
“investigator” and a “sponsor”. An “investigator” is defined as the individual who conducts 
the clinical investigation, whereas a “sponsor” is the individual person or funding entity or 
pharmaceutical organization that takes responsibility for and initiates the clinical 
investigation.(1) A sponsor does not perform the clinical trial unless the sponsor is 
simultaneously the investigator, who both initiates and conducts an investigation, taking on 
the regulatory obligations of both. The term sponsor-investigator refers only to an individual. 
A pharmaceutical company, hospital, or an academic institution cannot be a sponsor-
investigator because it is not an individual person.
Conducting an IIT as a sponsor-investigator commands considerable resources and 
infrastructure planning (see figure 1). This review points out important steps and 
requirements to start up an IIT. Based on the authors’ experience in running a multicenter 
trial in patients with ulcerative colitis, this review points out the critical steps required to set 
up an IIT. The trial with the acronym MERIT-UC (Randomized, double blind, prospective 
trial investigating the efficacy of Methotrexate in induction and maintenance of steroid-free 
remission in ulcerative colitis; ClinicalTrials.gov Identifier: NCT01393405) was funded by 
the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), initially in 
2010 with a Multi-Center Clinical Study Implementation Planning Grant (U34) followed in 
2011 by a cooperative agreement (U01) to conduct the study.(2) The results of this 
maintenance trial are expected in late 2017. The study recruited at 42 U.S. sites. All of these 
sites belong to the Clinical Research Alliance (CRA) of the Crohn’s and Colitis Foundation 
of America (CCFA), a group of academic medical centers, multi-specialty group practices, 
and private practices that conduct clinical trials in inflammatory bowel disease 
(www.CCFACRA.org).
From trial idea to starting a trial – necessary documents and regulatory 
requirements
At the core of a successful clinical trial is the generation of a compelling research question, 
the choice of the target population, intervention, comparison group and the measure and 
timing of the appropriate outcome criterion.(3) These factors have to be translated into a 
detailed clinical trial protocol. Several rubrics have been proposed for the development of a 
good research question and the construction of a trial protocol (table 1). The trial protocol 
comprises several essential sections ranging from the study population, the intervention, the 
outcome criteria, both favorable and harmful, and the statistical plan (table 2).
The adverse event section has to outline how these events are captured and reported. The 
focus is on the capture of treatment emergent adverse events (TEAE), which are defined as 
first to appear during treatment and were absent before treatment or which worsened relative 
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to the pre-treatment state. The reporting of TEAE can be simplified if a known drug with a 
defined adverse event profile is tested. In this case a separation between expected TEAE, 
which are based on the drug profile and unexpected TEAE can be made. This separation 
simplifies the reporting of TEAEs to institutional review boards (IRBs) and to data and 
safety monitoring boards (DSMBs). For the categorization of adverse events multiple 
classification systems have been described, but the most commonly used system is the 
Medical Dictionary for Regulatory Activities (MedDRA), which is also endorsed by the 
International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH).(4)
Another essential part of the protocol is the statistical plan, which describes how the study 
results are to be analyzed and reported. The plan should include hypotheses being tested, a 
sample size calculation, the level of significance and the procedures planned for missing 
data. The sample size calculation is an essential component of a randomized trial.(5, 6) The 
projected sample size significantly influences both the feasibility and the budget of the 
proposed trial. In IITs, sample sizes are often estimated using the maximum effect size with 
the aim of reducing the required sample size, which might improve the likelihood of funding 
by enhancing feasibility and minimizing budget requirements. However, this tends to 
increase the risk of a Type II error (the probability of making a false negative conclusion) 
due to underpowering of the study for an effect size less than the maximum. In contrast, 
sample size calculations commonly used in industry trials are designed to detect smaller 
differences in order to specifically reduce the Type II error probability, or equivalently, to 
increase the power of the study.
In case of a randomized, blinded IIT, all details of the randomization plan must be pre-
specified in the protocol. This includes the following detailed descriptions: who will 
construct the randomization table (i.e., study statistician) and what randomization schema 
will be used; who will be blinded; how will the randomization assignment be securely 
communicated to the pharmacy; how and when unblinding occurs if required for patient 
safety. For trials where it is anticipated that a large number of sites will each have a small 
number of patients, as it often occurs in IBD trials, permuted block randomization schemas 
help prevent drifting too far from designed balance of treatment assignment. For instance, 
using permuted blocks of size two or four ensures that every patient from sites having only 2 
or 4 patients will be distributed according to the design. Many small trials have inadvertently 
lost statistical power due to imbalanced treatment assignments when using simple 
randomization within site without use of blocking.
The establishment of a trial protocol is only a small part of the total work necessary to start a 
trial. The process can very broadly be categorized into 4 phases as shown in figure 2. After 
the protocol is finalized, several other documents need to be created. These include the 
informed consent form (ICF) and the case report forms (CRF). Both should be based on a 
finalized protocol to prevent unnecessary repeated adjustments of both documents. Another 
essential document is a manual of procedures (MOP) containing standard operating 
procedures that describe how to conduct every process at each study visit, including 
recruitment, consent, procedures for intervention and data gathering, data entry, and data 
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analysis. This manual guides the local investigators and coordinators in the performance of 
each patient encounter in an orderly and consistent fashion.
The finalized trial protocol, the ICF and the CRF need approval by the IRBs of all 
participating sites or in an optimal situation by a single central IRB.(7) A review of a multi-
site study by the IRB of each participating site involves significant administrative burden in 
terms of IRB staff and members’ time to perform duplicative reviews, which can take many 
months and significantly delay the launch of a trial. Use of single IRBs in multi-site studies 
has been shown to decrease approval times for clinical protocols and may be more cost 
effective than local IRB review.(8) However, not all sites will acknowledge or permit the 
involvement of a central IRB, presenting challenges in study organization.
In regard to forecasting the necessary timeframe for contract negotiations with the sites, 
longer contractual negotiations periods especially with academic sites should be expected. 
We suggest planning a time frame of at least 6–8 months from start of contract negotiation 
until final contract approval with an individual site. This time frame can be accelerated if 
master contracts between each site and a central organization (e.g. a pharmaceutical sponsor 
or a CRO) have previously been established.
In trials testing a new drug or device an Investigational New Drug Application or 
Investigational Device Exemption (IND/IDE) is required. Together with a finalized protocol 
a formal application needs to be submitted to the FDA. The submission to the FDA may 
additionally require an investigator brochure (IB). If the IIT will study medications that are 
already approved by the FDA, the approved package insert can serve as the core of the IB. If 
the IIT will test a new compound in development by an industry partner, the investigator will 
need to gather relevant data from the manufacturer. Lastly, if the IIT will test a new 
compound developed by the investigator-sponsor, the responsibility for documenting 
appropriate preclinical and early clinical data will fall on the study team. The FDA provides 
guidance for this process.(9). In the event the investigator is not sure whether or not an IND 
is necessary a short formal application for an IND exemption should be submitted. The FDA 
responds in a timeframe of 30 days if the exemption is granted or a full IND submission 
needs to be submitted.(10)
To prevent future acrimonious discussions about authorship at the publication stage of the 
trial, a document detailing the publication policy before recruitment begins is strongly 
recommended.(11) Guidance for a policy for multi-center studies in IBD can be found on 
www.ccfacra.org.
Clinical trial data capture
Clinical study data can be collected on paper CRFs, which are then transcribed into an 
electronic data capture system or by direct electronic collection and storage using an 
electronic record system (ERS). Implementation of an ERS has many significant advantages. 
First, with an ERS, data are entered in real time at each clinical site using web forms 
developed to replicate paper case report forms, resulting in increased speed of data 
collection and exchange. Secondly, the ERS enables extensive data validation at the point of 
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capture, reducing format errors, permissible value errors, and missing data, and ensuring a 
significantly more accurate and complete data set. Thirdly, web entry of data allows for web 
access to data, namely in reports that give up-to-date feedback about data quality and 
progress in the trial. Fourthly, a well-engineered ERS will facilitate adherence to protocol in 
all activities throughout the trial. In addition, ERS permits economical storage not only of 
clinical study data but other essential trial documents such as local IRB approvals and 
training documents thus easing the accessibility for the site coordinators and investigators. 
The ERS can be a convenient source of information to the sites when the study documents 
(protocol, CRFs, IB, MOP, newsletters, etc.) are stored and available for download. Finally, 
ERS facilitates real-time monitoring of the clinical study data.
It is important to work with your collaborating informatics team to complete engineering of 
study processes. This step, which includes the development of flow charts, a data dictionary, 
and validation specifications, is often overlooked because it is erroneously thought to delay 
the start of the trial. However, good engineering of the system ensures that your system will 
accurately reflect the protocol requirements, timely and effective capture high quality data, 
and roll out in the most cost effective manner. Making significant system changes after the 
trial is underway is both very costly and risky for adherence to the study protocol
The MERIT-UC study used an ERS system, which stored and archived all study relevant 
documents as well as the blinded patient data in one place. This system provided continuous 
support for the trial manager, the monitoring team, the site coordinators and the site 
investigators, thus allowing trial related issues to be resolved quickly, before these became 
major problems. However, one has to keep in mind that ERS still requires in person 
monitoring visits, but the monitoring process changes, since the monitor knows about the 
site's performance before visiting. Each audit is performed more to document what is 
already known rather than to learn for the first time how the site is performing. The result is 
a greatly enhanced relationship between site investigators and the monitors. The 
construction of a central ERS can be costly. The CCFA provides a central ERS in the setting 
of CRA studies as a service; however if studies are sponsored by NIH or other entities the PI 
of the study must create an ERS by e.g. using REDCap (http://projectredcap.org) for simple 
protocols, or by engaging with a research computing collaborator or a commercial vendor 
for more complex studies.(12–14)
Steering committee and Data and Safety Monitoring Board (DSMB)
Early in the planning phase the investigator should consider creating a steering committee. 
This committee should consist of specialists in the therapeutic area or key participants in the 
trial and if possible also a biostatistician. The steering committee will be charged with 
assisting in designing the study, maintaining the quality of study management, ongoing 
monitoring of individual toxicities and adverse events and writing the study publications. In 
addition to a steering committee, the NIH and FDA often recommend or require a DSMB for 
the appropriate oversight and monitoring of the conduct of clinical trials to ensure the safety 
of participants and the validity and integrity of the data. The establishment of a DSMB and a 
DSMB charter detailing the tasks of the DSMB is requested for multi-site clinical trials 
involving interventions that entail potential risk to the participants. However, a DSMB may 
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be also required for single-center phase 1 studies of a new drug or procedure that involves 
relatively high risk to a small number of participants. The DSMB functions and supervision 
of such activities are distinct from the requirement for study review and approval by an 
Institutional Review Board (IRB).(15)
Clinical trial infrastructure and trial budget
The PI has to build the trial infrastructure and coordinate with several committees including 
the steering committee, the DSMB, the sponsor, IRBs, necessary trial services (data 
managing center (DMC), trial monitoring, investigational drug services (IDS), central and/or 
local laboratories) (see figure 1). The steering committee, the IRB (central and local IRB’s), 
and the DSMB each have roles in the oversight of the trial. For data capture and analyses, 
the PI must coordinate the DMC, the data monitoring unit and the medical officer. In larger 
multi-center trials a medical officer for the independent evaluation and adjudication of 
TEAE and serious adverse events is often required.
Packaging, dispensing and tracking study medications and placebo is typically handled by 
an investigational drug service (IDS). In many IITs, the pharmaceutical company that 
manufactures the study drug supplies this directly to the IDS. When possible, the 
manufacturer may also supply matching placebo. However, when this is not possible, it may 
be necessary to have the IDS develop a placebo formulation.
There are many possible methods to create placebos, which are beyond the scope of this 
review; nevertheless, one needs to be carefully considered. If a placebo is to be developed or 
the study drug repackage, the IDS will need to support the PI in the IND process. In 
comparative effectiveness trials, these challenges may influence the choice between a 
blinded versus open label study. Since study drugs often have to be shipped across state 
borders, the drug shipments are subject to the legislation of the receiving state.(16) The IDS 
often requires licensure for each state to which it will need to ship drug. Therefore it is 
crucial for the PI and IDS to know about the legislative requirements surrounding the 
shipment and delivery processes of interstate shipment of investigational product to maintain 
compliance with all regulations. At the end of the study, the IDS will also be responsible for 
destroying any residual study medication.
Beyond the science and infrastructure planning a detailed budget estimate for the trail is 
crucial to determine if the study is financially feasible. The budget is also an essential part of 
any application process to a funding agency. The following expenditures for efforts of study 
personnel should be included on a per patient/per visit basis: a) obtaining medical history 
including current and past medications, b) evaluating disease activity (e.g. evaluation of 
clinical Mayo score), c) performing physical exam, and d) coordinating study procedures.
Additionally, every study should consider patient reimbursement e.g. for travel costs and lost 
work time. Procedures which are performed in the context of the trial (e.g. blood draw, 
radiological or endoscopic evaluations) also need to be also covered. A recent survey of 15 
academic centers active in the CCFA CRA revealed a wide range of procedural costs as 
outlined in table 3. It is important to proactively contact sites upfront to evaluate the costs 
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for specific procedures with which to estimate an optimal reimbursement scheme. Moreover, 
a straightforward cost analysis will help prevent situations in which sites fail to recruit due to 
financial burdens. Sites often waive the fees for IRB approval in the setting of an IIT.
Other factors that need to be considered in a trial budget are the charges of an IDS and 
expenses for monitoring of the trial. An IDS is necessary for acquisition and distribution of 
study and placebo drug to the sites. If the IRB permits an IDS to mail the study drug directly 
to the patient, no additional fees need to be calculated. However, if it is necessary for the 
local study site to dispense the drug or placebo to the patient, IDSs at each individual site 
also have to be reimbursed to provide these services. The monitoring budget includes cost 
estimates for the time and effort to train monitors for the specific trial, the required hours 
and fees to perform a monitoring site visit including the generation of a monitoring report 
(e.g. 8 hours/site/visit) and estimates of travel time and travel costs for the monitor to visit 
the sites. Collaboration with an informatics and data management group at the trial planning 
stage will allow for more accurate estimate of the costs for trial system development and/or 
customization and data management support. Given all the above cost factors and the 
procedural expenses outlined above and in table 3, the MERIT-UC budget exceeded $5 
million in direct costs, which is the current reality for a moderate-sized multi-center IIT in 
IBD. The amount of necessary funding also significantly limits the number of agencies able 
to support these types of trials.
Time and momentum are significant considerations in completing a multi-center trial. It is 
important to consider the local site perspective in recruitment rates. A slow-recruiting trial 
costs less to the study budget, but the local site still has to pay the study coordinator. If funds 
are not coming in regularly, the local PI and study coordinator will focus on other studies 
with easier recruitment or more lucrative payments. If recruitment slows, it is important to 
incentivize momentum, and it may be wise to allocate a portion of the budget for future 
incentives, or increasing the payment per subject in later years of the trial to compensate for 
inflation.
How to project recruitment into the trial?
IITs often fail due to insufficient enrollment of patients. Recruitment into IBD trials is 
increasingly difficult as the number of available therapies has expanded. One must consider 
all factors influencing trial recruitment including type of disease (e.g. early CD or UC), the 
allowed or excluded current or previous medications, the mode of application of the study 
drug, the frequency of endoscopies and study visits or the design of the trial with for 
example, the possibility for open label extension in case of no response or absence of a 
placebo arm in comparative effectiveness trials.(17–19) The number of active competing 
trials, especially industry sponsored trials should be evaluated, because reimbursements for 
sites are generally more generous in industry sponsored studies. Foreseeing approvals of 
new drugs for UC or CD might be helpful to estimate a realistic recruitment time, since 
approved new therapies influence the willingness of patients to participate in a trial and the 
clinical perspective of site investigators to recruit into the study.
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A guideline to estimate the number of patients a single site might recruit in 1 year can be 
based on previously published IITs in Crohn’s disease (CD) or ulcerative colitis (UC) (see 
table 4). The recruitment in these IIT, which targeted different disease stages (early, 
uncomplicated and late and complicated disease) and employed different study designs 
ranged from 0.7–2.5 patients/site/year. Globally conducted industry sponsored trials fair not 
much better in enrolling patients into trials. The CD PREVENT study (Prospective, 
Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 
REMICADE® and Placebo in the Prevention of Recurrence in Crohn’s Disease Patients 
Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence), recruited 297 
patients at 104 sites in 18 months (2010–2012 1.8 patients/site/year).(20)
Site management, recruitment, and enrollment
A crucial issue in IIT is the regular communication with sites to solve study related 
problems and to encourage enrollment into the study. For the startup of sites the local 
investigators and coordinators have to be trained on the protocol. This can be in the setting 
of a study meeting either in person, which is costly and often tedious to organize or via 
webinars. Regular newsletters sent by email or mail to the sites to address study related 
problems and encourage enrollment are a tool to keep the sites involved. The investigator or 
trial manager should also contact each site frequently and to solve recruitment questions. In 
a survey of 18 sites in the MERIT-UC trial, individual contact with the sites was 
unanimously the preferred method of communications, but a combination of web based 
meetings, regular newsletter and personal contact are most likely the most effective ways to 
manage trial problems and stimulate recruitment. Individual contact with sites is even more 
imperative due to a high turnover of study personnel.
Monitoring of study sites
Monitoring of a clinical trial assures a high quality of trial conduct. The tasks of "on site" 
monitoring are the evaluation of individual case histories of study participants, the 
assessment of site adherence to the protocol, the review of the ongoing implementation of 
appropriate data entry and quality control procedures, and essentially to assess adherence to 
good clinical practices. On-site monitoring might be required at the initial site selection to 
confirm that the site meets all study requirements. Monitoring represents a significant cost 
expenditure due to travel expenses and length of study visit. Thus some monitoring tasks 
such as review of regulatory files can be performed electronically if an ERS with such 
functions is in place (see table 5). However, only a physical site visit can establish the 
adequacy of study staff and facilities to conduct the study, to verify source documentation of 
eligibility of study subjects, to review the adherence to protocol and treatment plan, to 
confirm the drug accountability, and to validate source documentation of all data in the ERS. 
While the frequency of site visits is based on the study protocol, nonetheless at least 2 visits/
site should be planned: one shortly after the enrolment of the first or second patient to 
confirm the adherence to study procedures and another at study closure to review all enrolled 
subjects since the initial visit, resolution of queries from the DMC, and preparation for study 
storage. Budgeting for additional as-needed visits for sites with high enrollment to identify 
potential problems early in the study is wise.
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Challenges and lessons learned from the MERIT-UC trial
During the 8 years of planning, applying of funding and finally conducting the MERIT-UC 
study, the authors of this paper, who were all involved in the trial learned several important 
lessons, which are outlined in the following paragraphs:
If you conduct an IIT similar rules apply as in industry studies, meaning a lot of regulatory 
and infrastructural work has to be done. For this you need a large pool of knowledgeable 
co-investigators and co-workers
For MERIT-UC a considerable number of people were necessary to build the trial 
infrastructure. The core infrastructure comprised 25 persons. In addition to the PI and a 
fulltime study manager, 5 members in the steering committee and 2 biostatisticians helped to 
finalize the protocol and statistical plan. Six data specialists established the ERS, 2 monitors 
performed the monitoring tasks and travelled to the sites, 1 medical monitor oversaw the 
TEAE and SAE reporting and 2 administrators managed the contracts. Finally, a DSMB 
with 5 members had the oversight of the trial. Also, a single IDS at the University of 
Pennsylvania belonged to the core infrastructure MERIT-UC, which had the regulatory 
requirements in place to ship drug and placebo across state lines.
You need to be flexible to adapt the protocol (and often several other regulatory 
documents) if new medical knowledge emerges
One month before the planned start of recruitment, the FDA issued a warning for 
ondansentron and alerted of the risk of fatal arrhythmia. To comply with this warning we 
had to change the original plan to send each patient ondansetron to prevent MTX induced 
nausea. With the help of the IDS we replaced ondansetron with promethazine, but had to 
amend the protocol. This amendment, which had to be reapproved by IRBs of all 
participating sites, allowed for the dispensing of ondansetron if promethazine failed to 
alleviate the nausea but required the performance a normal electrocardiogram (ECG) by the 
sites. The costs for the ECG had to be added to the budget and the contracts had to be 
revised.
You need to be innovative and flexible in your budget and contract planning
Despite a provisional agreement with all local PIs for reimbursement for each enrolled 
patient, the actual contract negotiations could only be started once the U01 grant was 
presented. These negotiations took much longer than anticipated resulting in a launch delay 
of by 24 months after the initial funds were awarded. In fact, at the start of recruitment only 
6 sites were activated and it took an additional 12 months until finally all sites were 
recruiting patients. Also because recruitment time spanned over 4 years, reimbursement 
costs changed at many sites consequently the budget had to be adapted to prevent sites from 
halting recruitment since they were losing money on the study.
Recruitment in the realm of IBD is extremely difficult
MERIT-UC was initially conceptualized in 2007/2008 and recruitment was estimated based 
on the rosiglitazone in active ulcerative colitis study, which recruited between 2002–2006 
(table 4).(21)The plan for the trial was to activate 35 sites with the aim to include 6–8 patient/
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site in 3 years (around 2 patients/site/year). Only few clinical trials for patients with UC 
were available in the US at the time of conceptualization of MERIT-UC and the therapeutic 
alternatives for patients with steroid-dependent or mesalamine-resistant ulcerative colitis 
were very limited (azathioprine or infliximab). However, by the time the trial finally started 
in 2012, multiple industry sponsored phase 2 and 3 studies had been initiated (figure 3). 
Additionally, 3 biologics to treat UC were approved during the first 3 years of the study 
(adalimumab in 2012, golimumab in 2013 and vedolizumab in 2014), which affected 
recruitment. Despite the considerable number of sites, and uncomplicated in- and ex-clusion 
criteria as well as an open label induction period, recruitment for MERIT-UC was a 
challenge resulting in an average recruitment pace of only 1 patients/site/year. Eight sites 
had to be closed during the trial due to problems in recruiting for the trial or departure of the 
local principal investigator. Thus additional 7 new sites had to be found and activated, which 
were not easy tasks due to competing industry trials. Moreover, in contrast to professional 
research organizations (such as Parexel, Quintiles, Icon, Robarts and others), which have 
years of experience in finding reliable trial sites, IITs may have more problems in 
identifying new investigators outside of defined clinical research clusters such as the CCFA 
CRA.
You need to watch your sites
We observed a high turnover of study coordinators at many sites necessitating repeated 
training on the study protocol. Over the 4 years of the recruitment period, we experienced a 
turnover of >140 coordinators and 6 principal site investigators. To keep track of all the 
necessary regulatory changes in the setting of these staff changes, the electronic monitoring 
of the study documents was extremely helpful. Initially 3 monitoring visits were planned at 
each site, but ultimately 24 additional visits were necessary to underperforming sites or sites 
with a higher than expected volume.
Conducting a clinical trial is highly rewarding
There are several aspects, which make the successful completion of an IIT rewarding. 
Clinical research is conducted to improve or expand available medical treatments. Thus the 
outcome of an IIT can have a considerable impact on the care of patients. The established 
infrastructure of a large trial will strengthen the site of the PI and facilitate the funding of 
future studies not only of the PI but also of coworkers. IIT provide an entry point into the 
clinical trial landscape and as the PI of an IIT you regularly come in contact with numerous 
investigators within your research community. Thus you may find new collaborations for 
novel diagnostic or therapeutic approach and ultimately all these interactions will improve 
the lives of your patients. In our case a study investigating the therapeutic value of different 
diets, planned to start sometime 2017–2018, was also conceptualized based on experiences 
collected in MERIT-UC.
Conclusion
Due to numerous legal, contractual and infrastructural requirements, the conduct of IITs in 
the US in the context of current regulatory, research and clinical practices, is extremely 
complex. Investigators should allocate sufficient time to achieve milestones in each phase of 
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a startup of a multi-center clinical trial. In addition to the protocol and multiple other 
mandated documents, a well-balanced and realistic budget builds the foundation for eventual 
success. Furthermore, recruitment into IBD trials is extremely challenging and a sufficient 
number of sites should be engaged. Once the trial is in the recruitment phase the most 
critical part is to maintain study momentum, stimulate the eagerness of the investigators to 
actively participate in the trial and assure ongoing data quality. To better navigate these 
complex processes and master all the known and unknown hurdles in the trial process the PI 
requires a reliable trial infrastructure guided by a core team of committed support staff with 
in depth knowledge of the regulatory requirements and practical aspects of implementing a 
clinical trial.
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Multi-center clinical trial infrastructure.
IDS, Investigational drug service; DMC, data management center; DSM, data and safety 
monitoring board; SC, steering committee;
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Milestones of trial management.
*Essential documents: Financial disclosure forms, investigators curriculum vitae, FDA form 
1572, protocol signature pages, Good clinical practice (GCP) training certificates. 
Abbreviations: ICF, informed consent form, CRF, case report form; MOP, Manual of 
procedures; IB, Investigator brochure; PP, publication policy; IND/IDE, Investigational New 
Drug Application or Investigational Device Exemption.
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Industry sponsored interventional phase 2 and phase 3 studies in CD and UC in the US 
between 01/01/2005-01/01/2015 as listed on ClinicalTrials.gov. Only studies in adult 
patients with the following known statuses were counted: recruitment, completed, (with or 
without results), terminated with results. Trials evaluating the efficacy of mesalamine 
products in UC were excluded from the analyses.
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Table 1
FINER criteria for a good research question and PICOT criteria to construct the framework of the study and to 
aid protocol development. Adapted from (22, 23)
FINER Criteria PICOT criteria
Feasible • Adequate number of subjects
• Adequate technical expertise
• Affordable in time and money
• Manageable in scope
Population • What specific patient 
population is targeted?
Interesting • Investigators, peers and 
community are interested in 
the outcome of the study
Intervention • What is the 
investigational 
intervention?
Novel • New finding or confirms, 
refutes or extends previous 
findings
Comparison group • What is the correct 
comparison group for 
the intervention?
Ethical • Will be approved by 
institutional review boards 
and FDA (if IND is needed)
Outcome • What is the intended 
aim/outcome of the 
study?
Relevant • To scientific knowledge
• To clinical and health policy
• To future research
Time • What is the appropriate 
time to assess the 
outcome?
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Table 2
Required contents of a Clinical Trial Protocol. Additional sections describing the clinical necessity for this 
trial and a description of how the results of the trial will impact the future care in IBD is often required by the 
potential funding agencies.
• Introduction/Background
• Objectives of the study
• Trial Design (open label, double or single blinded)
• Study population with in and exclusion criteria
• Concomitant medication (allowed and not allowed)
• Definition of primary and secondary study endpoints
• Study procedures with detailed description of each study visit
• Adverse events, classification and reporting
• Criteria for withdrawal or stop of study drug
• Information of study medication supply
• Randomization, data management and data monitoring
• Statistical analyses including power analysis for the study*
*
A separate statistical analysis plan might be required
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Table 3
Procedural costs and fees for an IBD IIT in the US. Survey conducted in 2014/2015 at 15 academic IBD sites 
of the CCFA CRA.
Costs ($)
Procedure/Fees Mean Max
Upper-endoscopy + biopsy 2682 5500
Colonoscopy + biopsy 3235 6000
Sigmoidoscopy + biopsy 1983 3851
MR-Enterography 2312 3851
CT-Enterography 1745 6032
Chest x-ray 187 491
Coordinator/hr 94 250
PI/hr 177 300
Clinic space/hr 119 200
Pharmacy start up 2037 2893
Site start up 4698 8000
Abbreviations: PI, principal investigator; MR, magnet resonance tomography; CT, computed tomography.
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Table 5
Necessary documents in an Investigator’s File (Essential Documents):
• Protocol, initial and amended, signed and dated by PI
• Delegation of Authority signature form
• Form FDA 1572
• Investigator’s and co-investigator’s CV
• Financial agreement with sponsor
• Investigational Brochure
• Laboratory ranges and certification
• Investigational Drug Receipt & Disbursement Accountability Logs
• IRB Review Documentation, including approved subject communication, advertisements, etc.
• IRB approved Informed Consent Forms
• vHIPAA approval documentation and relative forms
• Subject screening, enrollment and ID code logs
• IND Safety Reports
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